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Abstract: In 125 early breast cancer patients who underwent multiple bone marrow aspirates, there was no signiﬁ  cant 
difference in terms of disease-free and overall survival after a median follow-up of 163 months between the patients with 
or without micrometastasis at the time of primary surgery. However, when the time-dependent evolution of the bone marrow 
aspirates was taken into account, some evidence for a longer disease-free and overall survival was found for the patients 
with negative bone marrow
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Introduction
Epithelial cells in bone marrow may be a prognostic factor in patients with primary breast cancer (BC). 
We have previously found that the evolution of bone marrow micrometastases in a series of women 
with primary breast cancer diagnosed between 1990 and 1994 did not correlate with treatment 
or non-treatment [1,2], or prognosis. We here update the ﬁ  ndings after a median follow-up of 163 months 
of women who underwent bone marrow analysis at the time of surgery and every 6–8 months 
afterwards.
Patients and Methods
Between January 1990 and December 1993, 125 patients with operable (stage I and II) breast cancer 
admitted to the Department of Medical Oncology of the University of  Verona underwent bone marrow 
aspiration at the time of surgery, called Time 0, and repeated in respect of patient compliance every 
6–8 months, starting at the end of adjuvant chemotherapy or at the ﬁ  rst 6–8 month follow up time. The 
bone marrow preparation procedure has been previously described [2]. The samples were processed 
for leukocyte separation, used to prepare cytospin slides, stained with a pool of monoclonal antibodies 
(including MBr1, MBr8, MOV8, MOV16 and MluCI, provided by Dr. M.I. Colnaghi, Istituto Nazionale 
Tumori, Milan, Italy). We here describe the 13-year follow-up analysis with the estimated disease-free 
(DFS) and overal survival (OS).
Data Analysis
The probabilities of DFS and OS were estimated using the product-limit method [3]. The effect of 
micrometastases on relapse-free and overall survival was evaluated using Cox’s proportional hazards 
model [4]. The signiﬁ  cance tests were based on the likelihood ratio statistic. The time-dependent evo-
lution of bone marrow status as a possible prognostic factor was evaluated using the approach suggested 
by Andersen and Gill [5], who reformulated the proportional hazards model as a counting process.
Results
The 125 women were followed up to 31/8/2005, for a median follow-up of 163 months. During the 
observation period, 54 patients (43.2%) relapsed and 45 (36.0%) died; the ﬁ  rst bone marrow sample was 
positive in 17 of the relapsing patients (31.5%) and 15 of those who died (33.3%). Of the 71 non-relpsing 488
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patients and 80 survivors, respectively 22 (31.0%) 
and 24 (30.0%) had a positive ﬁ  rst bone marrow 
sample.
The 10-year probability of relapse-free survival 
was quite similar in the patients with micrometa-
stases (0.632; 90% C.I.: 0.515−0.774) and in those 
without (0.572; 90% C.I.: 0.488−0.670). Similar 
results were found for overall survival, where the 
10-year survival probability was respectively 0.683 
(90% C.I.: 0.569−0.820) and 0.674 (90% C.I.: 
0.592−0.767). Cox’s model showed that the hazard 
for both relapse and death was not signiﬁ  cantly 
different between patients with and without micro-
metastases at the time of surgery.
However, the result of a bone marrow aspirate 
can be considered a time-dependent variable, 
because at subsequent evaluations, a previously 
positive result can disappear or a shift from a nega-
tive to a positive result can be found. For example, 
in the 74 patients with two aspirates, a shift from a 
negative to a positive result (−/+) was found in 8 
women, while a shift from a positive to a negative 
result (+/−)was found in 14 women. The exact 
binomial test for paired proportions yielded a p value 
of 0.286, thus indicating no signiﬁ  cant difference in 
the probability of the −/+ and +/− patterns.
As a matter of fact, there were a total of 32 shifts 
in the 26 patients who had more than one aspirate. 
To account for the time-dependent evolution of the 
bone-marrow aspirate, the approach of Andersen 
and Gill [5] was employed. Brieﬂ  y, as time marches 
onward, we observe the results for a subject; the 
data for a woman with one or more shifts are pre-
sented as multiple “observations”, each of which 
applies to an interval of her follow-up time.
After having taken into account the time-
dependent evolution of the bone-marrow aspirates, 
the hazard ratio of relapse (positive vs negative 
bone marrow) was 1.87 (90% C.I.: 1.09−3.22), and 
that of death was 1.79 (90% C.I.: 1.05−3.05).
Discussion
Metastasis, the spread of invasive carcinoma to 
sites distant from the primary tumor, is responsible 
for the majority of cancer-related deaths. Despite 
progress in other areas of cancer therapeutics, the 
complexities of this process remain poorly under-
stood. The long prevailing model of metastasis 
recognizes the importance of both “seed” and 
“soil” for metastatic progression [6]. Much 
attention has been paid to the relationship between 
the presence of cancer cells in bone marrow and 
patient outcome. Most published papers report an 
association between bone marrow positivity and a 
poor prognosis in breast cancer patients [1,8–25], 
including a recent meta-analysis [25] that found a 
correlation with micrometastases in bone marrow 
at the time of diagnosis in 4703 patients after a 
median follow-up of 5.2 years. Even with a median 
follow-up of almost 14 years, we did not ﬁ  nd this 
correlation when we only considered the aspirates 
taken at the time of surgery, i.e. the ﬁ  rst aspirates, 
but found it almost reached statistical signiﬁ  cance 
in terms of both DFS and OS when all of the aspi-
rates were included. In other words there is the 
evidence that the bone marrow evolution over time, 
rather than bone marrow status at the time of sur-
gery, seems to have a potential prognostic role. 
However on the other hand one reason for reaching 
no signiﬁ  cance might be that many breast cancer 
cells were proved to be apoptotic and so without 
any consequences for the patient.
Our analysis is characterised by the particularly 
large number of multiple bone marrow aspirates, 
which were repeated, according to patient com-
pliance, every 6–8 months starting from the time 
of surgery and the very long median follow-up (163 
months). However we should consider that the 
possibility to repeat the bone marrow aspirates over 
time is invariably linked to the disease evolution. 
The results suggest that bone marrow micrometa-
stases probably have a major impact on DFS and 
OS for at least 10 years after diagnosis, and that 
ﬁ  nding a second bone marrow aspirate positive is 
more informative than ﬁ  nding a positive ﬁ  rst aspi-
rate. We could speculate that probably a long lasting 
cross talk between “seed” and “soil” may be more 
signiﬁ  cant in inducing the metastatic process.
However many factors could help to interpret 
our results on such an interesting and intriguing 
topic, still arising many questions.
Firstly a better understanding of the relationship 
between bone stromal components, cancer cells and 
hematopietic cells. In fact recently much attention 
has focused on understanding the molecular and 
genetic factors that confer an intrinsic metastatic 
advantage to certain tumor cells. Meanwhile, chan-
ges occurring within distant tissues, creating a “soil” 
conducive for tumor invasion, have been largely 
neglected. Recent work characterizing the importance 
of bone marrow-derived hematopoietic progenitor 
cells in initiating these early changes has opened 
new avenues for cancer research and chemotherapeutic 489
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targeting [26]. In fact bone marrow-derived 
hematopoietic progenitor cells recently emerged as 
key players in initiating these early changes, creating 
a receptive microenvironment at designated sites 
for distant tumor growth and establishing the “Pre-
Metastatic Niche” [27]. This insight into the earliest 
stages in the metastatic cascade revises our concept 
of the metastatic “microenvironment” to include 
physiological cells recruited from the bone marrow. 
Moreover, the concept of pre-metastatic tissues as 
‘niches’ similar to physiological stem cell niches 
establishes a paradigm in which disseminated tumor 
cells may reside within a highly deﬁ  ned microcosm, 
both supportive and regulatory, and which may 
confer speciﬁ  c functions on indwelling cells. Under-
standing the cellular and molecular cross-talk 
between “seed” and “soil” may further our under-
standing of the factors that govern both site-speciﬁ  c 
patterning in metastasis and the phenomenon of 
tumor dormancy. This may lead to therapeutic stra-
tegies to detect and prevent metastasis at its earliest 
inception.
Secondly a greater knowledge of the biologic 
factors of primary tumors could be helpful; in fact 
even if the prognostic signiﬁ  cance of disseminated 
tumor cells in the bone marrow of breast cancer 
patients has been demonstrated in many studies, 
yet, it is not clear which of the primary tumors’ 
biological factors predict hematogenous dissemi-
nation [28] and it’s still under investigation.
Thirdly the technics used have also to be 
considered. Over the past 15 years early tumor 
cell dissemination has been detected in patients 
with breast cancer using sensitive immunocyto-
chemical and molecular assays based on the use 
of MAb and PCR, respectively. Tumor cells have 
been detected either directly, using immunocyto-
chemical staining, or indirectly, using reverse 
transcription-polymerase chain reaction (RT-PCR) 
as recently published [29–31]. These studies car-
ried out in both primary and metastatic breast 
cancer patients described the methodologies and 
markers used, and improvements in detection 
methodologies that are being investigated inclu-
ding real-time RT-PCR, novel markers, enrichment 
and automated image analysis. Additionally advan-
tages and limitations of the technics used to detect 
cancer cells have been analysed by many authors 
[30–33]. Advanced methods for molecular 
characterization of single tumor cells and the sur-
rounding environment have been developed lately, 
and this approach allows new insights into the 
metastatic cascade and characterization of targets 
for therapeutic approaches.
Taken together all this observations lead to the 
conclusion that, even if started many years ago and 
using the technics available at that moment, our 
study, thanks to the very long follow up time and 
the high number of bone aspirates taken, has to be 
considered in interpreting the role of bone marrow 
micrometastasis in breast cancer patient long term 
outcome.
Further prospective studies are required to 
examine this possibility in greater detail, with 
particular reference to early node-negative breast 
cancer and the value of adjuvant systemic therapy 
in patients with bone marrow micrometastasis, 
above all after a long follow-up. Further studies 
are also needed to increase the sensitivity and 
reproducibility of detecting micrometastases by 
technologically advanced means such as PCR or 
by using different monoclonal antibodies.
Disclosure
The authors report no conﬂ  icts of interest.
References
[1]  Molino, A., Pelosi, G., Turazza, M. et al. 1997. Bone marrow 
micrometastases in 109 breast cancer patients: correlation with 
clinical and pathological features and prognosis. Breast Cancer Res. 
Treat., 42:23–30.
[2]  Molino, A., Pelosi, G., Micciolo, R., Turazza, M. et al. 1999. Bone 
marrow micrometastases in breast cancer patients. Breast Cancer 
Res. Treat., 58:123–30.
[3]  Kaplan, E.L. and Meier, P. 1958. Nonparametric estimation from 
incomplete observations. J. Am. Stat. Associ., 53:457–81.
[4]  Cox, D.R. 1972. Regression model and life tables (with discussion). 
J. Roy. Stat. Soc., (B), 34:187–220.
[5]  Andersen, P. and Gill, R. 1982. Cox’s regression model for counting 
processes, a large sample study.
[6] Weigelt, B., Peterse, J.L. and van’t Veer, L.J. 2005. Breast 
cancer metastasis: Markers and models. Nature Reviews. Cancer, 
5:591–602.
[7]  Salvadori, B., Squicciarini, P., Rovini, D. et al. 1990. Use of  Monoclonal 
Antibody MBr1 to Detect Micrometastases in Bone Marrow Specimens 
of Breast Cancer Patients. Eur. J. Cancer, 26(8):865–7.
[8] Kirk,  S.J., Cooper, G.G., Hoper, M. et al. 1990. The prognostic 
signiﬁ  cance of marrow micrometastases in women with early breast 
cancer. Eur. J. Surg. Oncol., 16:481–5.
[9]  Dearnaley, D.P., Ormerod, M.G. and Sloane, J.P. 1991. Micrometas-
tases in Breast Cancer: Long-term Follow-up of the First Patient 
Cohort. Eur. J. Cancer, 27(3):236–9.
[10]  Mansi, J.L., Easton, D., Berger, U. et al. 1991. Bone marrow micro-
metastases in primary breast cancer: prognostic signiﬁ  cance after 6 
years’ follow-up. Eur. J. Cancer, 27(12):1552–5.
[11]  Cote, R.J., Rosen, P.P. and Old, L.J. 1991. Detection of bone marrow 
micrometastases in patients with early-stage breast cancer. Diagn. 
Oncol., 1:37–42.
[12]  Diel, I.J., Kaufmann, M., Goerner, R. et al. 1992. Detection of tumor 
cells in bone marrow of patients with primary breast cancer: a pro-
gnostic factor for distant metastasis. J. Clin. Oncol., 10(10):1534–9.490
Molino et al
Clinical Medicine: Oncology 2008: 2
[13]  Harbeck, N., Untch, M., Pache, L. et al. 1994. Tumor cell detection 
in the bone marrow of breast cancer patients at primary therapy: 
results of a 3-year median follow-up. Br. J. Cancer, 69:566–71.
[14]  Ménard, S., Squicciarini, P., Luini, A. et al. 1994. Immunodetection 
of bone marrow micrometastases in breast carcinoma patients and 
its correlation with primary tumor prognostic features. Br. J. Cancer, 
69:1126–9.
[15]  Tagliabue, E., Porro, G., Barbanti, P. et al. 1986. Improvement of 
tumor cell detection using a pool of monoclonal antibodies. Hybri-
doma, 5:107–15.
[16]  Molino, A., Colombatti, M., Bonetti, F. et al. 1991. A comparative 
analysis of three different techniques for the detection of breast 
cancer cells in bone marrow. Cancer, 67(4):1033–6.
[17]  American Society of  Clinical Oncology, 1997. Recommended breast 
cancer surveillance guidelines. 15(5):2149–56.
[18]  Berger, U., Bettelheim, R., Mansi, J.L. et al. 1994. The relationship 
between micrometastases in the bone marrow, histopathologic 
features of the primary tumor in breast cancer and prognosis. Am. J. 
Clin. Pathol., 90:1–6.
[19]  Diel, I., Kaufmann, M. and Krempien, B. 1990. Immunocytochemi-
cal detection of tumor cells in bone marrow in patients with primary 
breast cancer. Br. J. Cancer, 62(12):3.
[20]  Cote, R.J., Rosen, P.P., Lesser, M.L. et al. 1991. Prediction of early 
relapse in patients with operable breast cancer by detection of occult 
bone marrow micrometastases. J. Clin. Oncol., 9(10):1749–56.
[21]  Mansi, J.L., Berger, U., Easton, D. et al. 1987. Micrometastases in 
bone marrow in patients with primary breast cancer: evaluation as 
an early predictor of bone metastases. Br. Med. J., 295:1093–6.
[22]  Osborne, M.P., Wong, G.Y., Cote, R.J. et al. 1991. Breast cancer 
micrometastases (BMM) in bone marrow: detection by ﬂ  uorescein-
labeled monoclonal antibodies (MABS) predicts early relapse. Proc. 
Am. Soc. Clin. Oncol., 10.
[23] Vredenburgh, J.J., Silva, O., Broadwater, G. et al. 1997. The signiﬁ  cance 
of tumor contamination in the bone marrow from high-risk primary 
breast cancer patients treated with high-dose chemotherapy and hema-
topoietic support. Biol. Blood Marrow Transplant., 3(2):91–7.
[24]  Braun, S., Vogl, F.D., Naume, B. et al. 2005. A pooled analysis of 
bone marrow micrometastasis in breast cancer. NEJM, 
353:793–802.
[25]  Kaplan, R.N., Psaila, B. and Lyden, D. 2006. Bone marrow cells in 
the ‘pre-metastatic niche’: within bone and beyond. Cancer 
Metastasis Rev., 25(4):521–9.
[26]  Schindlbeck, C., Kampik, T., Janni, W. et al. 2005. Prognostic 
relevance of disseminated tumor cells in the bone marrow and 
biological factors of 265 primary breast carcinomas. Breast Cancer 
Res., 7(6):R1174–85.
[27]  Slade, M.J. and Coombes, R.C. 2007. The clinical signiﬁ  cance of 
disseminated tumor cells in breast cancer. Nat. Clin. Pract. Oncol., 
4(1):30–41.
[28]  Benoy, I.H., Elst, H., Philips, M. et al. 2006. Prognostic signiﬁ  cance 
of disseminated tumor cells as detected by quantitative real-time 
reverse-transcriptase polymerase chain reaction in patients with breast 
cancer. Clin. Breast Cancer, 7(2):146–52.
[29]  Benoy, I.H., Elst, H., Philips, M. et al. 2006. Real-time RT-PCR. 
detection of disseminated tumour cells in bone marrow has 
superior prognostic signiﬁ  cance in comparison with circulating 
tumour cells in patients with breast cancer. Br. J. Cancer, 
13;94(5):672–80.
[30] Lacroix, M. 2006. Signiﬁ  cance, detection and markers of disseminated 
breast cancer cells. Endocr. Relat. Cancer, 13(4):1033–67.
[31]  Müller, V., Hayes, D.F. and Pantel, K. 2006. Recent translational 
research: circulating tumor cells in breast cancer patients. Breast 
Cancer Res., 8(5):110.
[32] Wölﬂ  e, U., Müller, V. and Pantel, K. 2006. Disseminated tumor cells 
in breast cancer: detection, characterization and clinical relevance. 
Future Oncol., 2(4):553–61.
[33]  Loo, W.T., Fong, J.H., Zhu, L. et al. 2005. The value of bone 
marrow aspirates culture for the detection of bone marrow 
micrometastasis in breast cancer. Biomed. Pharmacother., 
59(Suppl 2):S384–6.